Erik James Hasenoehrl

Biography

Publications

• An amiloride derivative is active against the F1Fo-ATP synthase and cytochrome bd oxidase of Mycobacterium tuberculosis.

  Hards K, Cheung CY, Waller N, Adolph C, Keighley L, Tee ZS, Harold LK, Menorca A, Bujaroski RS, Buckley BJ, Tyndall JDA, McNeil MB, Rhee KY, Opel-Reading HK, Krause K, Preiss L, Langer JD, Meier T, Hasenoehrl EJ, Berney M, Kelso MJ, Cook GM. Commun Biol 2022 02 24

• Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis.

  Hasenoehrl EJ, Wiggins TJ, Berney M. Front Cell Infect Microbiol 2024

• Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis.

  Lee BS, Hards K, Engelhart CA, Hasenoehrl EJ, Kalia NP, Mackenzie JS, Sviriaeva E, Chong SMS, Manimekalai MSS, Koh VH, Chan J, Xu J, Alonso S, Miller MJ, Steyn AJC, Grüber G, Schnappinger D, Berney M, Cook GM, Moraski GC, Pethe K. EMBO Mol Med 2021 01 11

• Derailing the aspartate pathway of Mycobacterium tuberculosis to eradicate persistent infection.

  Hasenoehrl EJ, Rae Sajorda D, Berney-Meyer L, Johnson S, Tufariello JM, Fuhrer T, Cook GM, Jacobs WR, Berney M. Nat Commun 2019 09 16

• Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria.

  Lee BS, Kalia NP, Jin XEF, Hasenoehrl EJ, Berney M, Pethe K. J Biol Chem 2019 02 08